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Abdominal-class homeodomain-containing (Hox) factors form multimeric complexes with TALE-class ho-
meodomain proteins (Pbx, Meis) to regulate tissue morphogenesis and skeletal development. Here we have
established that Pbx1 negatively regulates Hoxa10-mediated gene transcription in mesenchymal cells and
identified components of a Pbx1 complex associated with genes in osteoblasts. Expression of Pbx1 impaired
osteogenic commitment of C3H10T1/2 multipotent cells and differentiation of MC3T3-E1 preosteoblasts.
Conversely, targeted depletion of Pbx1 by short hairpin RNA (shRNA) increased expression of osteoblast-
related genes. Studies using wild-type and mutated osteocalcin and Bsp promoters revealed that Pbx1 acts
through a Pbx-binding site that is required to attenuate gene activation by Hoxa10. Chromatin-associated Pbx1
and Hoxa10 were present at osteoblast-related gene promoters preceding gene expression, but only Hoxa10 was
associated with these promoters during transcription. Our results show that Pbx1 is associated with histone
deacetylases normally linked with chromatin inactivation. Loss of Pbx1 from osteoblast promoters in differ-
entiated osteoblasts was associated with increased histone acetylation and CBP/p300 recruitment, as well as
decreased H3K9 methylation. We propose that Pbx1 plays a central role in attenuating the ability of Hoxa10
to activate osteoblast-related genes in order to establish temporal regulation of gene expression during
osteogenesis.
Embryonic patterning of the skeleton is a complex process
responsible for regulating the positional identity, shape, and
size of skeletal primordial elements by an intricate orchestra-
tion of signaling molecules and transcriptional regulators. The
most widely studied transcriptional regulators governing em-
bryonic patterning are the Hox homeodomain DNA-binding
proteins. Several emerging lines of evidence have demon-
strated that these Hox proteins play a wider role, extending
their functions from patterning the developing embryo to reg-
ulating formation and maintenance of mature tissues such as
bone (13, 18, 19, 21). In adults, bone turnover is a continual
process of resorption and renewal that depends on the com-
mitment of mesenchymal progenitors to the osteoblast lin-
eages. This process is mediated by a variety of extracellular
signals that are also necessary for embryonic skeletal develop-
ment, including canonical Wnt signals and bone morphoge-
netic proteins (BMPs) (5, 12, 27). Homeodomain proteins,
including the abdominal-class Hox family, have been identified
as downstream targets and regulators of osteogenic BMP sig-
naling (23, 25, 26). One of the more compelling questions
regarding Hox function is the mechanism(s) by which these
proteins regulate transcription in a cell-specific manner to pro-
mote mature tissue regeneration.
Several abdominal-class Hox proteins are upregulated in
bone repair, including Hoxa2, Hoxd9, Hoxa11, and Hoxa13
(15, 24), suggesting that the embryonic program is reactivated
during new bone formation. For example, Hoxa10 is strongly
induced in osteoblasts immediately following BMP2 treatment,
coincident with the robust expression of Runx2, the master
regulator of osteoblast commitment (2). Hoxa10 has been
shown to bind to several phenotypic bone promoters at Hox
consensus sequences and to enhance osteocalcin (bglap2; Ocn)
transcriptional activity in reporter assays in vitro (19). Al-
though the exogenous expression of Hoxa10 can induce the
transcription of several bone genes in normal osteoblasts,
Hoxa10 binds to chromatin of endogenous bone genes preced-
ing the binding of Runx2 (19). Hoxa10 has been postulated to
mark chromatin for activation by allowing Runx2 binding and
subsequent gene expression. It is important to note that during
osteoblast differentiation phenotypic genes are temporally ex-
pressed, and this sequential pattern of expression suggests that
several chromatin remodeling factors are required for osteo-
blastic gene activation. Perhaps due to the critical but varied
roles of Hox proteins, a large complement of coregulatory
molecules serve as coactivators or corepressors of Hox-medi-
ated transcriptional activity, functioning by direct protein-pro-
tein interactions or by modulating Hox DNA-binding activity
(31).
One of the best characterized groups of Hox-interacting
proteins is the three-amino-acid loop extension (TALE) family
of homeodomain-containing transcription factors, which in-
cludes the pre-B-cell leukemia homeobox protein 1 (Pbx1).
Like Hox proteins, Pbx1 plays a critical role in patterning of
the axial skeleton, with deletion of the gene resulting in severe
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skeletal malformations due to defects in chondrocyte matura-
tion (40). Pbx1 regulation of skeletal development has been
shown to be both dependent and independent of Hox protein
involvement (6, 31). Several TALE proteins are closely related,
but loss of Pbx2 or Pbx3 does not confer a skeletal phenotype
(36, 41); thus, Pbx1 may have a distinct role during skeletal
development. Furthermore, mapping of polymorphisms re-
lated to bone mineral density in Chinese populations revealed
a strong correlation between nucleotide variation in the PBX1
gene and decreased bone mass (10). It has been suggested that
during mesenchymal cell commitment to the myogenic lineage,
Pbx proteins may act as “pioneer” transcription factors that
penetrate repressive chromatin and mark specific genes for
activation by MyoD (38). In this study we addressed the func-
tional role of Pbx1 in osteogenesis and the Hoxa10-dependent
activation of the osteocalcin and bone sialoprotein (Bsp) genes
as classical models for osteoblast-specific gene expression.
MATERIALS AND METHODS
Cell culture. Human embryonic kidney cells (HEK-293T), mouse preosteo-
blasts (MC3T3-E1), and mesenchymal cells (C3H10T1/2) were obtained from
ATCC (Manassas, VA). HEK-293T and MC3T3-E1 cells were maintained in
minimum essential medium alpha medium (MEM) (Invitrogen/Gibco Carls-
bad, CA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan,
UT), 2 mM L-glutamine, and 100 U/ml of penicillin and 100 g/ml streptomycin
(Pen/Strep). C3H10T1/2 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen/Gibco) containing 10% FBS, 2 mM L-glutamine,
and Pen/Strep. Primary rat osteoprogenitors were isolated from embryonic (day
21) rat calvaria as previously described (16). Osteoprogenitor cells were main-
tained in Dulbecco’s minimal essential medium (MEM) (Invitrogen/Gibco) con-
taining 10% FBS, 2 mM L-glutamine, and Pen/Strep. To induce osteogenic
differentiation, media were further supplemented with BMP2 (100 ng/ml) (gen-
erously provided by John Wozney [Wyeth Research, Women’s Health and Mus-
culoskeletal Biology, Cambridge, MA]) and/or 280 M ascorbic acid and 10 mM
-glycerophosphate (GP) (Sigma Aldrich, St. Louis, MO). Media were re-
placed every 2 days for the duration of all experiments. All cells were maintained
at 37°C in a humidified 5% CO2 environment.
Expression constructs and short hairpin RNA (shRNA) virus generation. The
Xpress-Pbx1 plasmid used in this study was previously described (19). The
Flag-Pbx1 construct was generated by excising the Pbx1 fragment from pCMV-
Pbx1 (generously provided by Corey Largman, University of California, San
Francisco) by BamHI digestion followed by ligation into linearized pCDNA3
(Invitrogen). To create the Pbx1-pSuper construct used for lentiviral packaging,
a PCR fragment of Pbx1-pCDNA3.1, containing the cytomegalovirus (CMV)
promoter, Pbx1 sequence, and poly(A) signal with additional EcoRI and ClaI
overhangs, was generated and ligated into linearized pSuper vector. Pbx1-
shRNA pGIPZ plasmid was obtained from Open Biosystems (Thermo Fisher
Scientific, Huntsville, AL). All plasmids were either entirely or partially se-
quenced to ensure fidelity at the University of Massachusetts Medical School
sequencing facility (Worcester, MA).
For viral packing, lentiviral vectors containing Pbx1 or Pbx1-shRNA sequences
were cotransfected along with pMD2.G and pCMVR-8.91 (generously pro-
vided by Didier Trono; Addgene plasmids 12259 and 12263) viral plasmids into
HEK293T cells. Cells were propagated for approximately 48 h posttransfection,
and the supernatant was collected, analyzed for titer in HEK293T cells, and
subsequently used for infections.
Antibodies. The following antibodies were used for Western blotting: anti-
Pbx1 (P-20, sc-889; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-
Hoxa10 (N-20, sc-17158; Santa Cruz), anti-Runx2 (monoclonal, clone 8G5; MBL
International, Woburn, MA), anti-histone deacetylase 1 (anti-HDAC1) (05-641;
Upstate/Millipore, Billerica, MA), and anti-HDAC3 (B-12, 39500; Active Motif,
Carlsbad, CA). The following antibodies were used for immunoprecipitations
and/or chromatin immunoprecipitations and immunohistochemistry: anti-RNA
polymerase II (Pol II) (clone 8WG16; Covance), anti-Runx2 (M-70, sc-10758;
Santa Cruz), anti-Hoxa10 (N-20X, sc-17158X; Santa Cruz), anti-Pbx1(4342; Cell
Signaling Technology, Danvers, MA), CBP (C-20, sc-10758; Santa Cruz), anti-
p300 (N-20, sc-584; Santa Cruz), anti-penta-acetylated histone H4 (06-946; Up-
state), anti-histone H3 acetylated lysine 9 (07-352; Upstate), anti-histone H4
acetylated lysine 16 (ab1762; Abcam, Cambridge, MA), anti-HDAC2 (C-19,
sc-6296; Santa Cruz), anti-HDAC6 (L-18, sc-5258; Santa Cruz), and anti-histone
H3 dimethyl lysine 9 (ab9050; Abcam).
Immunohistochemistry. Long bones of 2-day-old mice were fixed with PLP
fixative (2% paraformaldehyde, 0.075 M lysine, 0.037 M sodium phosphate, 0.01
M periodate, pH 7.4) for 48 h. The fixed long bones were then demineralized by
successive treatment with 18% EDTA (disodium salt dihydrate, pH 7.4) for 14
days, dehydrated, and embedded in paraffin using standard procedures. Paraffin-
embedded tissues were sectioned (5 m), adhered to glass slides, and rehydrated,
and antigens were recovered by treatment with retrieval buffer (1 mM Tris, 0.5
mM EGTA, pH 9.0). Sections were blocked with phosphate-buffered saline
supplemented with 1% bovine serum albumin, 0.05% saponin, and 0.2% gelatin.
Serial sections were incubated overnight at 4°C with anti-Pbx1 (Cell Signaling),
anti-Hoxa10 (N-20), or anti-Runx2 (M-70) diluted (1:100) in phosphate-buffered
saline (PBS) supplemented with 0.1% bovine serum albumin and 0.3% Triton
X-100. Labeling was visualized with species-specific horseradish peroxidase-
conjugated secondary antibody (P448, 1:200; Dako). Sections were counter-
stained with methyl green (0.5% methyl green, 0.1 M sodium acetate trihy-
drate, pH 4.2) or toluidine blue (0.1% toluidine blue, 7% ethanol, 150 mM
sodium chloride, pH 2.3).
Transfection and reporter assays. A 1.1-kbp DNA fragment encompassing the
proximal, tissue-specific promoter of the rat osteocalcin gene was inserted into
pGL3 basic vector as previously described (16). A pGL3 basic vector containing
a 938-bp region of the rat bone sialoprotein proximal promoter region was
previously described (34) (generously provided by the late Jaro Sodek, University
of Toronto). Alteration of the Pbx or Hox DNA consensus sequence was per-
formed by using a QuikChange site-directed mutagenesis kit (Stratagene, Cedar
Creek, TX). Cells were transfected with 500 ng of reporter plasmid and the
indicated concentrations of Hoxa10, Pbx1, or pCDNA 3.1 expression vector using
FuGENE6 transfection reagent according to the manufacturer’s instructions
(Roche). At 16 to 24 h posttransfection, cells were scraped into PBS, collected by
centrifugation, and lysed with 5 passive lysis buffer (Promega, Madison, WI). In
each experiment, cells were also cotransfected with phRL-null Renilla luciferase
plasmids for normalization. Firefly and Renilla luciferase activities were assayed
using the dual-luciferase reporter assay system according to manufacturer’s in-
structions (Promega). Experiments were performed in triplicate and results dis-
played as mean values  standard errors of the means (SEM).
RNA isolation and RT-qPCR. Total RNA was isolated using Trizol reagent
(Invitrogen) according to the manufacturer’s specifications. DNase I-treated
total cellular RNA was primed with oligo(dT) and reverse transcribed into
cDNA using the Superscript first-strand cDNA synthesis kit (Invitrogen) accord-
ing to the manufacturer’s instructions. Gene expression was determined by quan-
titative real-time reverse transcription-PCR (RT-qPCR) using Power SYBR
green PCR master mix (Applied Biosystems Inc., Foster City, CA) and gene-
specific primers in an ABI Prism 7000 thermocycler. For each gene, expression
levels were normalized to GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase). Experiments were performed in triplicate and results displayed as mean
values  SEM.
Immunoblotting. Cells were lysed in direct lysis buffer (2% SDS, 10 mM
dithiothreitol [DTT], 10% glycerol, 12% urea, 10 mM Tris-HCl [pH 7.5], 1 mM
phenylmethylsulfonyl fluoride [PMSF], 1 protease inhibitor cocktail [Roche],
25 M MG132 [proteasome inhibitor]) and boiled for 5 min. Samples were
quantified, and equal amounts of protein were resolved by SDS-PAGE. Proteins
were transferred to a polyvinylidene difluoride membrane and were subjected to
immunoblotting with the appropriate antibodies. Immunoreactive proteins were
detected using Western Lightning chemiluminescence reagent (Perkin-Elmer,
Boston, MA).
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed
as previously described (17). Briefly, formaldehyde cross-linking was performed
for 15 min, and cells were collected in 1 PBS and then lysed in lysis buffer (25
mM Tris-HCl [pH 8.0], 5 mM MgCl2, 10 mM EDTA, 1% SDS, 1% Triton X-100,
162.5 mM NaCl, 25 M MG-132, and 1 Complete protease inhibitor). Lysates
were sonicated to obtain DNA fragments with an average size of 0.2 kbp to 0.6
kbp. In some experiments, chromatin was treated with PstI restriction endonu-
clease (NEB, Danvers, MA) for 2 h at 37°C. Immunoprecipitations were per-
formed with the appropriate antibodies or immunoglobulin G (IgG) as a control.
Immune complexes were collected, followed by recovery of DNA.
Sequential ChIP studies were performed using the primary pulldown from one
antibody, which was divided into equal aliquots for the second pulldown with
antibodies specific for coregulatory molecules. Instead of the elution step (1%
SDS and 100 mM Na2HCO3) after washing, immunocomplexes were eluted in 10
mM DTT. The eluate was further diluted 1:40 in ChIP dilution buffer (0.01%
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SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM Tris-HCl [pH 8.1], 167 mM
NaCl) and used for the secondary immunoprecipitations.
Aliquots of each recovered DNA sample were assayed by quantitative PCR to
detect the proximal Ocn promoter region spanning bp 198 to 28 upstream of
the transcription start site. As a control for nonspecific binding/proper DNA
fragmentation, a region of the Ocn distal promoter from bp 1377 to 1184 was
also analyzed. The oligonucleotides used were as follows: proximal promoter,
5-GGC AGC CTC TGA TTG TGT CC-3 (198 to 179) and 5-TAT ATC
CAC TGC CTG AGC GG-3 (47 to 28); Pbx site, 5-GTC TCT AGG GCC
AGC CAG TGC-3(305 to 285) and 5-AGG CTG CCG GGT CCT GAC
AT-3(211 to 190); Hox site, 5-CCT ATT GCG CAC ATG ACC CCC A-3
(112 to 91) and 5-GCA CCG AGT TGC TGT GTG GGA-3(5 to 	 15);
and distal promoter, 5-TGT CTT CAG GCA CAC CAG AAG-3 (1377 to
1356) and 5-AAA TCT GCA GCC GTT CCC CCA GT 3 (1207 to
1184). Samples were normalized to the initial input and expressed as percent
chromatin pulldown (compared to input).
Immunoprecipitations. Initially, protein A/G plus agarose beads (Santa Cruz)
(100 l; 1:1 beads/PBS) were noncovalently complexed with 20 to 100 g of
specific antibody. Unbound antibodies were washed away with phosphate-buff-
ered saline (PBS), and antibody-bound protein A/G agarose was resuspended in
100 l PBS. Disuccinimidyl suberate (DSS) cross-linker (Pierce) was dissolved in
dimethyl sulfoxide (DMSO) and added to the antibody-protein A/G solution at
a final concentration of 1 mM. The cross-linking reaction was performed at room
temperature for 1 h. Excess DSS was removed by washing the resin four times
with 400 l of Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.2),
four times with 0.1 M glycine (pH 2.8) to remove free antibody, and finally three
times with TBS. The cross-linking efficiency was evaluated by A280. Approxi-
mately 107 cells per immunoprecipitation were lysed in 500 l of Nonidet P-40
(NP-40) lysis buffer (150 mM NaCl, 50 mM Tris [pH 8.0], 1% NP-40, 1
Complete protease inhibitor [Roche], 25 M MG132 [Sigma Aldrich]) for 15
min at 4°C. Cell lysates were sonicated, followed by centrifugation at 16,000  g
for 15 min at 4°C. The supernatant was transferred to a clean microcentrifuge
tube and precleared with 40 l of protein A/G plus agarose beads at 4°C for 30
min. To precipitate immunocomplexes, 50 l of antibody-protein A/G plus
agarose complex was added and incubated at 4°C with agitation for 1 to 4 h.
Beads were washed three times with 1 PBS containing 1 protease inhibitors
and eluted in 50 l 0.1 M glycine (pH 2.8). Samples were neutralized by addition
of 50 l Tris-HCl (pH 9.2), denatured by addition of 6 sample buffer followed
by boiling for 5 min, and then analyzed by Western blotting.
Statistical analysis. Statistical analysis was performed using Prism software
(Graphpad Software, La Jolla, CA). Gene expression data were repeated at least
three times and analyzed by one or two-way analysis of variance (ANOVA)
followed by the Bonferroni posttest. Chromatin immunoprecipitation data were
repeated at least two times and analyzed by Student’s t test.
RESULTS
Pbx1 is highly expressed in osteoprogenitors and decreases
during osteoblast differentiation. Pbx1 is strongly associated
with skeletal patterning during embryonic development (40);
however, the expression profile of Pbx1 from mesenchymal
progenitors through stages of osteoblast differentiation is not
clear. The commitment to the osteoblast phenotype is normally
characterized by expression of specific genes (e.g., Runx2, the
alkaline phosphatase gene [Alp], Bsp, and Ocn) at defined time
points (Fig. 1A), and we sought to determine the expression of
Pbx1 through these defined stages. We used two different pro-
genitor cell lines representing distinct stages of commitment to
the osteoblast lineage. When treated with BMP2 or dexametha-
sone to induce osteoblast differentiation, C3H10T1/2 cells, a
model of multipotential mesenchymal progenitors, exhibited
decreased Pbx1 mRNA expression (Fig. 1B) and protein levels
(Fig. 1C). Analysis of lineage-committed MC3T3-E1 preosteo-
blastic cells revealed that Pbx1 expression was relatively high
during the proliferative stage (day 4) but decreased consis-
tently after day 15 with maturation of the osteoblast precursors
(Fig. 1D). Correspondingly, Pbx1 protein levels were reduced
at later stages of the differentiation time course (Fig. 1E). In
contrast, mRNAs of other TALE family proteins (Pbx2, Pbx3,
and Meis1) were detectable at low levels and did not decline
during osteoblast differentiation (Fig. 1D). These findings sug-
gest that unlike other TALE family members, Pbx1 is specifi-
cally downregulated during differentiation to a mature osteo-
blast.
Pbx1 is expressed in the bone environment. We sought to
determine if the pattern of Pbx1 expression observed in ma-
turing osteoblasts was indicative of protein expression in native
bone. Immunohistochemical staining of mouse long bones re-
vealed that Pbx1 was expressed in bone marrow cells and
proliferating chondrocytes but could not be observed in hyper-
trophic chondrocytes (Fig. 2A). Pbx1 was also expressed in
preosteoblasts and active osteoblasts on newly forming trabec-
ular bone (Fig. 2A, G, and J). On the periosteal bone surface,
robust Pbx1 staining could be observed in muscle cells and
osteoprogenitors but not in mature osteoblasts (cells directly
FIG. 1. Pbx1 expression decreases during osteoblast differentia-
tion. (A) Schematic illustrating temporal gene expression during
osteoblast differentiation. Osteoblast-like differentiation was in-
duced in C3H10T1/2 cells by treatment with either 2% FBS (control),
100 ng/ml BMP2, or 10 nM dexamethasone for 7 days. (B) Relative
mRNA expression of Pbx1 in C3H10T1/2 cells was determined by
RT-qPCR. (C) Protein expression was determined by Western blotting
using an anti-Pbx1 antibody. MC3T-3E1 cells were treated with 280
M ascorbic acid–5 mM -glycerol phosphate to induce osteogenic
differentiation for a total period of 28 days. (D) Total RNA was
isolated, and relative expression of TALE protein family genes was
determined by real-time quantitative PCR using gene-specific prim-
ers. (E) Relative protein expression of Pbx1 over the 28-day time
course was determined by Western blotting using an anti-Pbx1
antibody. Error bars indicate SEM.
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adjacent to new bone) (Fig. 2D and J). In contrast, Hoxa10
could be observed in most cells within cartilage, bone, and
muscle (Fig. 2B, E, H, and K), while Runx2 was restricted
primarily to hypertrophic chondrocytes and osteoblasts and
was not expressed in bone marrow or muscle (Fig. 2C, F, I, and
L). These findings suggest that in bone Pbx1 is present in
osteoprogenitor cells but is reduced in mature osteoblasts,
supporting the notion that Pbx1 is downregulated during os-
teoblast maturation.
Pbx1 functionally impairs osteoblast differentiation. To un-
derstand the contribution of Pbx1 in commitment and main-
tenance of the osteoblast lineage, Pbx1 was exogenously ex-
pressed in C3H10T1/2 cells under the control of a CMV
promoter using recombinant lentivirus. Increased virus titer
demonstrated a dose-dependent correlation with Pbx1 protein
levels (Fig. 3A), and high expression of Pbx1 was maintained
over the 12-day experimental period (data not shown).
C3H10T1/2 cells were infected with Pbx1 or control (green
fluorescent protein [GFP]) lentivirus and treated with BMP2
to induce osteoblast differentiation. Pbx1 overexpression de-
creased alkaline phosphatase activity by 50% compared to
controls (Fig. 3B). Examination of a panel of osteoblast mark-
ers (Alp, Runx2, Ocn, and Bsp) by RT-qPCR also showed
significant (P 
 0.01) reductions (10 to 25% of control values)
in expression of these endogenous genes in response to Pbx1
(Fig. 3C). Similarly, C2C12 cells (a mesenchymal/myogenic
progenitor with osteoblastic potential) examined under the
FIG. 3. Overexpression of Pbx1 results in decreased expression of
osteoblast-related genes in mesenchymal progenitor cells. (A) C3H10T1/2
cells were infected with several concentrations (50, 100, and 200
PFU/cell) of recombinant lentivirus encoding Pbx1. Relative expres-
sion of Pbx1 was determined by Western blotting using an anti-Pbx1
antibody (N-20; Santa Cruz) followed by detection with anti-rabbit-
horseradish peroxidase (HRP)/ECL reagent. (B) and C) C3H10T1/2
cells were infected with 100 PFU/cell of recombinant lentivirus (EV
or Pbx1). Cells were then treated with BMP2 or vehicle (PBS) for 7
days. (B) C3H10T1/2 cells overexpressing Pbx1 demonstrated less
alkaline phosphatase activity. Scale bar, 500 m. (C) Total RNA was
isolated from C3H10T1/2 cells, and relative expression of osteoblast-
related genes was determined by RT-qPCR using gene-specific prim-
ers. (D and E) MC3T3-E1 cells were infected with 100 PFU/cell of
recombinant lentivirus (EV or Pbx1) and treated with 280 M ascorbic
acid–5 mM -glycerol phosphate to induce osteogenic differentiation
for a period of 6 and 12 days. (D) MC3T3-E1 cells were fixed and
stained for alkaline phosphatase activity. (E) Total RNA was isolated
from MC3T3-E1 cells, and relative expression of osteoblast-related
genes was determined by RT-qPCR using gene-specific primers. Sta-
tistical significance was determined by one-way ANOVA followed by a
Bonferroni posttest. Data are presented as the means from three
experiments  SEM.
FIG. 2. Pbx1 is expressed in bone but not in mature osteoblasts.
Two-day-old mouse long bones were demineralized and stained for
Pbx1, Hoxa10, or Runx2 as indicated. (A, B, and C) Mouse femur
region displaying proliferating chondrocytes (pc), trabecular bone (tb),
bone marrow (bm), and hypertrophic chondrocytes (hc). (D, E, and F)
Cortical bone demonstrating muscle (m), periosteal region (p), and
mature bone (b). Scale bar, 200 m. (G to L) High-magnification
images (scale bars, 50 m) for cortical bone with adjacent periosteum
and muscle, showing fibrous capsule (fc), osteoprogenitors (op) with
robust Pbx1 staining, and mature osteoblasts (ob) (G, H, and I), and
for trabecular bone, demonstrating newly formed bone (nb) with many
osteoprogenitors (op) surrounding calcified cartilage (cc) (J, K, and L).
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same conditions demonstrated a significant (P 
 0.01) de-
crease in BMP2-induced osteoblastogenesis in response to
Pbx1 (see Fig. S1 at http://labs.umassmed.edu/steinlab/). Our
studies with the committed preosteoblast MC3T3-E1 cells also
echoed a reduction in osteoblast-specific differentiation by
Pbx1 expression from the onset of alkaline phosphatase activity
(day 6) through the matrix maturation stage (day 12) (Fig. 3D).
Due to the committed osteogenic phenotype of MC3T3-E1
cells, Pbx1 had no effect on expression of the early osteogenic
marker Runx2 (day 12), while mature osteoblast genes Bsp and
Ocn were significantly (P 
 0.01) decreased, by 50% (Fig. 3E).
Taken together, these findings indicate that Pbx1 is a
negative regulator of mesenchymal progenitor commitment
to the osteoblast phenotype as well as the maturation of
osteoprogenitors.
Pbx1 negatively regulates osteogenic genes: depletion of
Pbx1 by shRNA increases osteoblast differentiation. The re-
duction of osteoblast markers by Pbx1 overexpression in dif-
ferentiated cells suggested that Pbx1 may have a biological role
in attenuating osteoblast-specific gene expression. To address
this question, several Pbx1 shRNAs were generated and exog-
enously expressed in C3H10T1/2 cells using recombinant len-
tivirus. All three Pbx1 shRNA sequences (T1, T2, and T3)
successfully decreased Pbx1 protein levels (Fig. 4A). This de-
crease in Pbx1 levels was maintained for the period of the
experiments (20 days) (data not shown), and the shRNA
construct generating the most efficient knockdown (T2) was
used for subsequent studies. C3H10T1/2 cells with reduced
Pbx1 expression exhibited increased (3-fold) alkaline phos-
phatase activity and expression compared to cells infected with
the nonsilencing (NS) control (Fig. 4B). Additionally in Pbx1-
shRNA-infected cells, Ocn and Bsp mRNA levels, markers of
the mature osteoblast, were upregulated 5- to 6-fold compared
to NS control cells (Fig. 4C), while Runx2 mRNA levels did not
change significantly. Pbx1-shRNA resulted in a similar en-
hancement of osteoblast differentiation in MC3T3-E1 cells,
with significant (P 
 0.01) increases in Alp activity and Alp,
Ocn, and Bsp mRNA levels compared to those in NS-infected
controls but no change in Runx2 mRNA (Fig. 4D and E).
These findings are consistent with the Pbx1 expression profile
in osteoblasts (Fig. 1 and 2) and forced-expression studies (Fig.
3) and establish that Pbx1 is a potent negative regulator of
osteoblastic genes expressed during early and late stages of
osteoblast differentiation.
A Pbx1 regulatory element is required to inhibit Hoxa10-
mediated activation of osteocalcin and bone sialoprotein pro-
moters. The potent effects on osteoblast gene expression me-
diated by alteration of Pbx1 expression levels suggested that
Pbx1 may directly regulate bone-related gene promoter activ-
ity. Pbx1 has been demonstrated to bind directly to DNA and
modulate the binding of Hox proteins for several promoters
(22). We sought to determine if the negative regulation of the
osteoblast phenotype by Pbx1 was dependent on the putative
Pbx regulatory elements (33) located in the proximal promot-
ers of several bone-related genes, including Bsp and Ocn. To
address this question, Pbx1 and Hoxa10 expression plasmids
were cotransfected with luciferase reporter constructs contain-
ing approximately 1 kbp of the Ocn (1.1 kbp Ocn-Luc)
(Fig. 5A) or Bsp (938 bp Bsp-Luc) promoter region (see
Fig. S2 at http://labs.umassmed.edu/steinlab/). MC3T3-E1
preosteoblasts transfected with Hoxa10 in addition to the Ocn
or Bsp luciferase reporter exhibited significantly (P 
 0.01)
increased luciferase activity (5- to 6-fold) (Fig. 5A and data not
shown). However, cotransfection of cells with Hoxa10 and
Pbx1 along with either reporter construct (Ocn or Bsp) resulted
in a 75% decrease in luciferase activity compared to that in
cells transfected with Hoxa10 alone (Fig. 5A; also see Fig. S2
at http://labs.umassmed.edu/steinlab/). There was no change in
luciferase activity in cells transfected with Pbx1 alone. These
results indicate that Pbx1 acts to reduce Hoxa10-mediated
transcriptional activation at bone-specific promoters.
We next identified that the Pbx1-binding site is functionally
active by determining that in vitro-translated (IVTT) recombi-
nant Pbx1 and MC3T3-E1 nuclear protein extracts could bind
to the radioactively labeled probe (Ocn promoter sequence
GGCAGCCTCTGATTGTGTCC) by electrophoretic mobility
shift assay (see Fig. S3 at http://labs.umassmed.edu/steinlab/).
FIG. 4. Depletion of Pbx1 by shRNA results in increased expres-
sion of osteoblast-related genes in mesenchymal cells. (A) to C)
C3H10T1/2 cells were infected with 100 PFU/cell of shRNA-encod-
ing recombinant lentivirus (nonsilencing [NS] or three different Pbx1-
specific targets [T1, T2, and T3]). C3H10T1/2 cells were then treated
with 100 ng/ml BMP2 or vehicle (PBS) for a period of 7 days. (A) Relative
protein levels of Pbx1 in treated C3H10T1/2 cells were determined by
Western blotting using an anti-Pbx1 antibody. (B) C3H10T1/2 cells
treated with Pbx1-shRNA, demonstrating increased alkaline phos-
phatase activity. Scale bar, 500 m. (C) Relative expression of
osteoblast-related genes, monitored by RT-qPCR, was significantly
increased in Pbx1-shRNA-infected C3H10T1/2 cells. (D and E)
MC3T3-E1 cells were infected with shRNA-containing lentivirus
(as described above) and treated with 280 M ascorbic acid–5 mM
-glycerol phosphate for a period of 12 days to induce osteogenesis.
(D) MC3T3-E1 cells treated with Pbx1-shRNA demonstrated in-
creased alkaline phosphatase activity. (E) Relative expression of
osteoblast-related genes in MC3T3-E1 cells was determined by RT-
qPCR. Statistical significance was determined by one-way ANOVA
followed by a Bonferroni posttest. Data are presented as the means
from three experiments  SEM.
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The presence of the Pbx1 consensus sequence or Pbx1 antibody
reduced binding of Pbx1 to the labeled oligonucleotide in both
recombinant protein and MC3T3-E1 nuclear extracts.
We next addressed whether the putative Pbx site is directly
involved in binding Pbx1 and plays a role in Hoxa10 repression.
An Ocn reporter plasmid with the Pbx site mutated was co-
transfected with Hoxa10, which resulted in similar levels of
Hoxa10-mediated activation as with the wild-type (WT) Ocn
plasmid (Fig. 5B). However, cotransfection of the mutant Pbx-
Ocn promoter with both Hoxa10 and Pbx1 did not show the
expected decrease in Hoxa10 stimulated activity (Fig. 5B).
Similar results were observed for the equivalently mutated Bsp
promoter (see Fig. S2 at http://labs.umassmed.edu/steinlab/).
Thus, the Pbx-binding sequence is required for Pbx1-mediated
repression of Hoxa10 transcriptional activity. This conclusion
is further supported by mutation of the Hox-binding sequence
in the Ocn promoter, which resulted in significantly (P 
 0.01)
reduced luciferase activity when cotransfected with Hoxa10
expression plasmid (Fig. 5C, bars 1 and 3). The weak level of
activity of the mutHox-Ocn reporter (Fig. 5C) could be due
to the contribution from increased Runx2-mediated
transcriptional activity, as Hoxa10 can directly upregulate
Runx2 expression (19). However, all Hox-mediated activation
is significantly (P 
 0.05) decreased by cotransfection of Pbx1
(Fig. 5C). Taken together, these results provide direct evidence
that Pbx1-DNA interactions are required to block Hoxa10-
mediated transcriptional activation of osteoblast-related genes.
Pbx1 is associated with repression of chromatin remodeling
on the osteocalcin promoter. Our previous findings identified
Hoxa10 as an early activator of bone gene expression and
demonstrated that Hoxa10 functions by facilitating the remod-
eling of chromatin (18). Given the role of Pbx1 as a mediator
of Hox function, we sought to establish if Pbx1 is associated
with chromatin remodeling of the temporally expressed osteo-
calcin gene during osteoblast differentiation. The Ocn gene
promoter (Fig. 6A) and the Bsp promoter (see Fig. S4A and B
at http://labs.umassmed.edu/steinlab/) are strongly regulated
by chromatin structure and are tightly packaged as
heterochromatin in proliferating cells (day 4) (32). During
transcriptional activation, the proximal promoter must
adopt an open conformation to allow binding of
transcriptional regulators, resulting in an exponential in-
crease in gene expression (day 12) (Fig. 6B). By chromatin
immunoprecipitation analysis, Pbx1 is strongly associated
with the Ocn and Bsp promoters prior to expression (day 4)
but not during exponential gene expression (day 12) (Fig. 6C;
also see Fig. S4C at http://labs.umassmed.edu/steinlab/). This
result was in contrast to the pattern observed with RNA
polymerase II and known transcriptional activators (e.g.,
Runx2 and Hoxa10), all of which demonstrated increased Ocn
promoter occupancy with increased Ocn gene expression (Fig.
6C). Several mediators and covalent modifications of histone
proteins associated with chromatin remodeling, including CBP/
p300, acetylated histone H4, and acetylated H4 lysine 16
(H4K16), were found to increase with osteoblast differentiation
(Fig. 6D; also see Fig. S4D at http://labs.umassmed.edu/steinlab/),
although acetylation of H3 lysine 9 (H3K9) was unchanged. In
contrast repressive marks on chromatin, including histone
deacetylases (HDAC) 1, 2, and 3, as well as methylation of
histone H3K9, demonstrated a decrease upon osteoblast
FIG. 5. Alteration of Pbx1 consensus sequence in the osteocalcin
promoter results in decreased attenuation of Hoxa10 activity.
MC3T3E1 preosteoblasts were transfected with 500 ng of the indicated
luciferase reporter plasmids as well as the indicated amounts (ng) of
pCDNA3, pCDNA-Hoxa10, and/or pCDNA-Pbx1, and relative lucif-
erase activity was assessed with a luminometer. (A) Luciferase re-
porter construct (pGL3-Basic) containing the 1.1-kb region of rat
Ocn (1.1 kb Ocn-Luc). Hoxa10-mediated luciferase reporter activity
was significantly decreased upon cotransfection of Pbx1. (B and C) The
1.1-kb Ocn-luc plasmid was modified by site-directed mutagenesis to
alter the putative Pbx1 DNA consensus sequence (1.1 kb mutPbx-
Ocn-Luc) or the Hox DNA consensus sequence (1.1 kb mutHox-
Ocn-Luc). (B) Alteration of the Pbx1 DNA consensus sequence re-
sulted in loss of Pbx1 repression of Hoxa10-mediated Ocn-luciferase
activity. (C) Alteration of Hox sequence resulted in a significant de-
crease in Ocn-driven luciferase activity and no significant activation in
the presence of Pbx1. Statistical significance was determined by two-
way ANOVA followed by a Bonferroni posttest. Data are presented as
the means from three experiments  SEM.
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differentiation (Fig. 6E; also see Fig. S4E at http://labs
.umassmed.edu/steinlab/). These results strongly suggest that
Pbx1 is associated with negative regulation of chromatin
remodeling at the osteocalcin and bone sialoprotein promoters.
To address whether there is a direct association of Hoxa10
and Pbx1 with regulators of chromatin remodeling at the os-
teocalcin promoter in differentiated osteoblasts, two-step chro-
matin immunoprecipitation (ChIP-reChIP) experiments were
performed using a primary pulldown with an anti-Hoxa10 or
anti-Pbx1 antibody. The chromatin fraction associated with
Hoxa10 at the Ocn promoter demonstrated a high level of
association with Pbx1, as the secondary pulldown with anti-
Pbx1 antibody resulted in a signal that was approximately
60% of the input (Hoxa10) (Fig. 7A). Consistent with the
primary ChIP analysis (Fig. 6C), the association of Pbx1
with the Hoxa10 chromatin fraction was greatly reduced at
day 12. In comparison, Runx2 was weakly associated with
the Hoxa10 chromatin fraction at day 4 and subsequently
increased at day 12. This increased binding of Runx2 in
association with Hoxa10 on the Ocn promoter at day 12
reflects upregulation of the Ocn gene, which is also demon-
strated by the 4- to 5-fold-increased association of the tran-
scriptional coactivator p300.
In contrast to Hoxa10, the Pbx1-Ocn chromatin fraction was
only weakly associated with Runx2, CBP, or p300 (by second-
ary pulldown) at either day 4 or day 12 (Fig. 7B), reflecting the
role of Pbx1 as a repressor of Ocn gene expression. However,
the Pbx1 chromatin fraction was strongly associated with
HDAC1 at the osteocalcin promoter when the gene was silent
during proliferation (day 4) and during bone-specific gene ex-
pression (day 12), and neither HDAC1 nor Pbx1 was strongly
associated with Hoxa10 at day 12. Due to the cooccupancy of
Pbx1 with negative regulators of chromatin remodeling at the
osteocalcin promoter during proliferation and differentiation
FIG. 6. Pbx1 displays a pattern of gene-repressive functionality on the osteocalcin promoter. (A) Diagram of rat osteocalcin promoter
displaying relative binding sites and primer sites used for chromatin immunoprecipitation analysis. Rat calvarial osteoblasts were isolated from
embryonic day 18.5 rat pups and collected during the proliferative stage (day 4) or cultured in differentiating conditions and collected during
exponential increase in osteocalcin expression (day 12). (B) Calvarial osteoblasts were analyzed at the indicated differentiation stages by RT-qPCR
to determine levels of osteocalcin gene expression. (C to E) The ChIP analysis was performed on cleared lysates from primary osteoblasts using
5 g of the indicated antibody. Recovered DNA was then quantified by qPCR using primers specific for the proximal promoter region of the
osteocalcin gene to determine relative occupancy of transcriptional activators (C), activation markers (D), or repressive markers (E). Statistical
significance was determined by Student’s t test (*, P
 0.05 versus matched control). ChIP experiments were repeated at least two times with similar
results, and one representative experiment is presented ( standard deviation [SD]).
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(Fig. 7B), we sought to determine if association of Pbx1 with
these factors (including Hoxa10) was by direct protein-protein
interactions. Chromatin digested with PstI restriction endonu-
clease to separate the Pbx and Hox binding sites was immu-
noprecipitated with Hoxa10, Pbx1, or control (IgG) antibodies
(Fig. 7C). DNA containing the Hoxa10-binding site could be
detected in both Hoxa10 and Pbx1 pulldowns by qPCR. Similar
results were observed for the Pbx1-binding site fragment, sug-
gesting that Hoxa10 and Pbx1 may interact through direct
protein-protein interactions on the Ocn promoter.
To detect other protein-protein interactions, whole-cell ly-
sates from confluent MC3T3-E1 cells were immunoprecipi-
tated with Hoxa10, Runx2, Pbx1, HDAC1, or control (IgG)
antibodies (Fig. 8A). Western blotting with anti-Hoxa10 and
anti-Pbx1 antibodies demonstrated that Hoxa10 and Pbx1 form
protein complexes with Runx2 and HDAC1 in osteoblasts.
Furthermore, immunoprecipitation using anti-HDAC1 fol-
lowed by Western blotting with anti-Pbx1 indicated that Pbx1
was present in complexes containing HDAC1 (Fig. 8B). Taken
together, these findings identify Pbx1 functions on bone gene
promoters (i) in osteoprogenitors prior to their expression by
interaction with HDACs and (ii) in postproliferative mature
osteoblasts, where Pbx1 dissociating from bone gene promot-
ers results in Hoxa10-mediated changes in chromatin remod-
eling to promote gene transcription.
Pbx1 gain of function and loss of function alter the chro-
matin remodeling profile at bone-related gene promoters.
Having established that Pbx1 was directly associated with reg-
ulators of chromatin remodeling, at both the protein-protein
and promoter-regulation levels, we hypothesized that modifi-
cation of Pbx1 levels in osteoblasts should alter the chromatin
profile at the osteocalcin promoter. Primary calvarial osteo-
blasts were treated with recombinant lentivirus to exogenously
overexpress Pbx1 (Fig. 9A) and analyzed by ChIP (Fig. 9B).
With increased Pbx1 expression, a corresponding increase in
Pbx1 together with significant increases in occupancy of his-
tone deacetylases HDAC1 and HDAC2 at the Ocn promoter
was evident. In primary osteoblasts with depleted Pbx1 expres-
sion (Pbx1-shRNA) (Fig. 9C), Pbx1 binding to Ocn chromatin
FIG. 7. Pbx1 cooccupancy with repressive histone-modifying en-
zymes and Hoxa10 on the osteocalcin promoter in proliferating cells.
Cross-linked cell lysates from primary calvarial osteoblasts were im-
munoprecipitated using either anti-Hoxa10 or anti-Pbx1 antibody, and
the resulting fraction was further immunoprecipitated using the spec-
ified antibodies (ChIP-reChIP). (A) The Hoxa10-immunoprecipitated
fraction was further immunoprecipitated using Hoxa10, Runx2, Pbx1,
CBP, p300, HDAC1, or control (IgG) antibodies and quantified by
qPCR. (B) The Pbx1-immunoprecipitated fraction was further immu-
noprecipitated using Hoxa10, Runx2, Pbx1, CBP, p300, HDAC1, or
control (IgG) antibodies and quantified by qPCR. (C) Cross-linked
chromatin from proliferating calvarial osteoblasts was treated with PstI
to cleave DNA between the Hoxa10- and Pbx1-binding sites, immu-
noprecipitated with anti-Hoxa10 or anti-Pbx1 antibody, and evaluated
with primer sets specific for digested (Pbx site [PS] or Hox site [HS])
or undigested (proximal promoter [Prox]) fragments. Statistical signif-
icance was determined by Student’s t test (*, P 
 0.05 versus matched
control). the ChIP experiment was repeated three times with similar
results, and the data presented are from one representative experiment
( SD).
FIG. 8. Pbx1 protein-protein interactions in osteoblasts. (A) Whole-
cell lysates from confluent MC3T3-E1 cells were immunoprecipitated
with Hoxa10, Runx2, Pbx1, HDAC1, or control (IgG) antibodies. Proteins
were resolved by SDS-PAGE, and Hoxa10 and Pbx1 were detected by
Western blotting with specific antibodies. (B) Lysates from MC3T3-E1
were used for immunoprecipitation using anti-HDAC1 followed by West-
ern blotting with anti-Pbx1 or specific HDAC antibody.
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was decreased compared to that in NS-infected cells, as would
be predicted based on reduced cellular levels of Pbx1 (Fig.
9D). While there was no effect on Hoxa10 binding, a large
increase in both Runx2 and p300 occupancy at the osteocalcin
promoter in cells deficient in Pbx1 as well as a reduction in
occupancy of HDAC1 and HDAC2 was found, consistent with
findings from ChIP-reChIP studies (Fig. 7). These results in-
dicate that Pbx1 may be important for recruiting these HDAC
factors to the osteocalcin promoter to mark the gene for ex-
pression while maintaining a repressive state during prolifera-
tion. The data suggest that Pbx1 contributes to the switching of
chromatin remodeling factors from repression to open chro-
matin for activation, as illustrated in Fig. 9E.
DISCUSSION
Here we have identified an integral role for the Hox-inter-
acting protein Pbx1 as an important regulator of the osteoblast
phenotype. Pbx1 acts to coordinate the temporal expression of
the Ocn and Bsp genes by Hoxa10 during osteogenesis. It is
apparent that Hox and TALE genes have defined roles in
embryonic development; however, our results indicate that
these proteins can have analogous or concordant roles in the
maintenance of adult tissues. It has been suggested that Pbx1,
as well as other TALE family proteins, can act in concert with
(1, 35) or independent of (4, 8) Hox proteins in its role of
regulating gene expression through direct binding to cognate
regulatory elements. We have provided several lines of evi-
dence that Pbx1 is a critical negative regulator of osteoblast
differentiation by demonstrating that (i) Pbx1 is highly ex-
pressed in osteoprogenitors and its expression at the transcript
and protein levels decreases upon commitment to the osteo-
blast phenotype and again during late stages of differentiation;
(ii) exogenous expression of Pbx1 or depletion by targeted-
shRNA expression inhibits or increases, respectively, osteo-
blastogenesis and the expression of osteoblast-related genes;
(iii) Pbx1 acts directly on the Ocn and Bsp promoters to repress
Hoxa10-mediated expression of the gene by a mechanism in
which Pbx1 recruits negative regulators of chromatin re-
modeling; and (iv) Pbx1 has the ability to act as a molecular
switch functioning with Hoxa10 in proliferating cells to
maintain osteoblast-specific genes in a repressed state and
facilitate Hoxa10 activation of gene promoters by dissociating
from the chromatin in differentiated cells. These key findings
highlight a novel regulatory role for Pbx1 to repress and mark
osteoblast genes for expression and limit Hoxa10-mediated
gene transcription for regulating the temporal activation of
postproliferative gene expression.
Our data suggest that Pbx1 has a role in attenuating osteo-
genesis by repressing osteoblast gene expression at several
stages. Increased Pbx1 expression in mesenchymal precursors
decreased expression of early osteoblast genes (Runx2 and Alp)
and late-stage genes (Bsp and Ocn), whereas decreased Pbx1
FIG. 9. Modification of Pbx1 levels in osteoblasts results in alter-
ation of histone-modifying enzymes at the osteocalcin promoter. (A
and B) Rat calvarial osteoblasts were isolated from embryonic day 18.5
rat pups and infected with Pbx1 or empty (EV) lentiviral constructs,
and cells were collected at 48 h after infection after just reaching
confluence (day 6). (A) Relative expression of the Pbx1 and Ocn genes
was monitored by RT-qPCR. (B) ChIP analysis was performed on
cleared lysates from primary osteoblasts using 5 g of the indicated
antibody. Recovered DNA was then quantified by qPCR using primers
specific for the proximal promoter region of the osteocalcin gene to
determine the relative occupancy of the indicated proteins. (C) Iso-
lated osteoblasts (as described above) were infected with Pbx1-shRNA
or nonsilencing shRNA (NS) lentiviral constructs, and relative expres-
sion of Pbx1 and Ocn was determined by RT-qPCR. (D) ChIP analysis
was performed on cleared lysates from treated primary osteoblasts (as
described above) to determine the relative occupancy of the indicated
proteins on the osteocalcin promoter. Statistical significance was de-
termined by Student’s t test (*, P
 0.05 versus matched control). ChIP
experiments were repeated two times with similar results, and the data
presented are representative of one experiment ( SD). (E) Schematic
model of Pbx-mediated repression of the osteocalcin gene.
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levels resulted in increased osteoblast gene expression. The
observation of enhanced commitment to the osteoblast phe-
notype in the absence of Pbx1 is concordant with reports of
premature mineralization of skeletal elements, particularly at
the hypertrophic chondrocyte zone, in growth plates in Pbx1-
null mice (40). In contrast to Pbx1-null mice, which die at
embryonic day 15, mice with knockouts of other TALE family
genes (Pbx2 and Pbx3) survive after birth and show only slight
skeletal defects, with no apparent effects on osteoblast differ-
entiation (7, 41). Meis1-null mice die due to defects in fetal
hematopoiesis and do not develop the skeletal abnormalities
observed in Pbx1/ mice (20), together suggesting that Pbx1
may have a specific role in the commitment of precursors to
the osteoblast lineage. It is interesting to note that conditional
Pbx1 deletion in hematopoietic stem cells results in loss of
self-renewal and the premature initiation of transcriptional
mechanisms, resulting in maturation of progenitor cells to a
differentiated state (14). Likewise, Pbx1 depletion from the
osteoprogenitor stage to the osteoblast appears to have a tem-
poral role in promoting differentiation. Thus, Pbx function is to
limit differentiation by maintaining a mesenchymal phenotype,
similar to the role of the protein in maintaining the embryonic
mesoderm (7).
Our previous studies demonstrated that Hoxa10 functions as
an immediate-early response to the osteogenic BMP2 signal
and is capable of inducing osteogenic gene expression. There-
fore, Hoxa10 is an important cofactor to establish the osteo-
blast phenotype (19). In this study, our findings show that Pbx1
occupies bone gene promoters coincident with Hoxa10, result-
ing in tempered Hoxa10-mediated gene expression. In com-
mitted osteoprogenitors where Pbx1 expression is robust, it is
clear that Pbx1 and Hoxa10 both bind to the osteocalcin pro-
moter preceding gene expression. These findings are consistent
with our earlier studies that showed a significant increase in
Hoxa10 occupancy of bone promoters that are expressed in
mature osteoblasts (19). Here we show that Hoxa10 is associ-
ated with chromatin of the actively transcribed genes (day 12).
The regulation of osteoblast genes by Pbx1 and Hoxa10
appears to be facilitated by the conserved organization of reg-
ulatory elements in the promoters of osteoblast-related genes.
The proximal promoter regions of several genes generally as-
sociated with bone formation feature multiple homeodomain-
binding DNA motifs, including some that preferentially bind
Pbx1 (tTGAC/T) (33). Strikingly in the Bsp and Ocn promot-
ers, the Pbx1 consensus sequence and the Hoxa10-binding site
flank functional Runx2-binding elements (16, 37) (Fig. 6A; also
see Fig. S4A at http://labs.umassmed.edu/steinlab/). The
regulation of the Ocn promoter by Hoxa10 involves the
accumulation of Hoxa10 on the Ocn promoter, peaking with
active gene transcription. This finding establishes a key event
for Hoxa10-mediated gene activation by dissociation of Pbx1
from the Ocn and Bsp genes when they are actively transcribed.
Coincident with the dissociation of Pbx1, there is an increase in
Runx2 and RNA Pol II, which marks the onset of active gene
transcription. Thus, we conclude from our studies of primary
osteoblasts progressing through stages of differentiation that
dissociation of Pbx1 may be an important step (or switching
mechanism) in allowing RNA Pol II and/or Runx2 recruitment
to these promoters, resulting in gene transcription.
Chromatin remodeling through the recruitment of histone-
modifying enzymes that regulate the methylation or acetylation
of lysine and arginine residues is a fundamental underlying
mechanism regulating transcription (29, 30). Hoxa10 as well as
Pbx1 has a defined role in the patterning of the axial skeleton
(6, 43, 44) by regulating chromatin remodeling that leads to
phenotypic gene expression in several tissues (4, 28). Pbx1 has
been demonstrated to be involved in chromatin remodeling
events leading to the activation of MyoD-dependent promot-
ers (such as myogenin), and the protein is constitutively bound
to silent chromatin prior to initiation of muscle differentiation
(4, 11). Supporting the concept that Pbx1 exerts functional
activity through epigenetic control, the pattern of histone mod-
ifications and histone-modifying enzymes at the osteocalcin
promoter indicates that Pbx1 is associated with a repressed
chromatin state and that the chromatin adopts an “active”
conformation marked by higher levels of H3K4 methylation
and acetylation upon Pbx1 dissociation. Several studies have
reported that HOX proteins (including Hoxa10) can mediate a
modified chromatin acetylation status leading to transcrip-
tional activation or repression by interacting with p300/CBP (3,
9, 42). The ChIP-reChIP experiments presented in this study
demonstrate that Hoxa10 is strongly associated with CBP at
the osteocalcin promoter during both proliferation and differ-
entiation and with p300 during differentiation, while Pbx1 is
localized on the osteocalcin promoter coincident with histone
deacetylases and Hoxa10 in proliferating cells. This result
would further imply that Pbx1 is a repressor of chromatin
remodeling and gene transcription in osteoblasts. Supporting
this model, it has been previously demonstrated that Hox-Pbx
complexes can promote histone deacetylation by recruiting
class I histone deacetylases to repress gene transcription (39).
It is therefore intriguing that when colocated at the osteo-
calcin promoter, Hoxa10 and Pbx1 have the characteristics
of both repressional and activational regulators, containing
both HDACs and histone acetyltransferases (CBP/p300). Our
findings suggest that even though Pbx1 is a strong inhibitor of
osteoblastogenesis, it may have a temporal role in assisting in
the activation of chromatin remodeling and support a switch-
ing mechanism from repression to activation.
In conclusion, in this study we have demonstrated functional
interactions between Pbx1 and Hoxa10 in progenitor cells and
osteoblasts for control of the temporal expression of bone-
specific genes at multiple levels, including transcriptional reg-
ulation at the promoter level and initiation of transcriptional
activity through chromatin remodeling. This characterization
of the Pbx1 and Hoxa10 interactions on the osteocalcin pro-
moter has provided a clearer understanding of the commit-
ment to an osteogenic lineage preceding Runx2 recruitment in
mesenchymal progenitors. This concept has implications for
bone repair and molecular intervention to correct bone disor-
ders.
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